Anitocabtagene autoleucel (anito-cel), a novel anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, shows promising results in relapsed and/or refractory multiple myeloma (RRMM) patients. Initial findings from the Phase 1 and ongoing Phase 2 trials indicate high response rates and manageable safety profiles.

Key Points:

• Anito-cel showed a 95% overall response rate in RRMM.
• Complete response and stringent complete response rate was 62%.
• 92% achieved minimal residual disease negativity.
• Median 6-month progression-free survival and overall survival rates were 90% and 95%, respectively.
• Manageable cytokine release syndrome and neurotoxicity observed.

Authors:
Ciara Louise Freeman, Binod Dhakal, Gurbakhash Kaur, Richard T. Maziarz, Natalie Callander, Adam S. Sperling, Carolina Schinke, Andrzej J Jakubowiak, Noa Biran, Douglas W Sborov, Cindy Varga, Abhinav Deol, Abraham S. Kanate, Mehmet Hakan Koçoğlu, Melhem M. Solh, Kamalika Banerjee, Rebecca Chan, Myrna Nahas, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher R. Heery, Tim Welliver, Krina K. Patel, Matthew Frigault